VONVENDI Approved to Treat Von Willebrand Disease

The U.S. Food and Drug Administration has approved Shire’s VONVENDI, a recombinant von Willebrand factor treatment for perioperative management of bleeding in adults 18 years and older with von Willebrand disease.

Expanding Uses of IVIG

Researchers are taking a closer look at intravenous immune globulin for its potential to stop the progression of multiple complex conditions from lupus to multiple sclerosis.

Superbug Apocalypse: A Post-Antibiotic Era?

BioSupply Trends Quarterly Spring 2017 Superbugs

Antibiotics are the most commonly prescribed drugs worldwide. But now, widespread antimicrobial resistance caused by environments, hosts and overmedication may soon be the demise of these “wonder drugs.”